JP2024530315A5 - - Google Patents
Info
- Publication number
- JP2024530315A5 JP2024530315A5 JP2024513277A JP2024513277A JP2024530315A5 JP 2024530315 A5 JP2024530315 A5 JP 2024530315A5 JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024530315 A5 JP2024530315 A5 JP 2024530315A5
- Authority
- JP
- Japan
- Prior art keywords
- ray powder
- crystalline form
- powder diffraction
- diffraction pattern
- morphology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/115718 | 2021-08-31 | ||
| CN2021115718 | 2021-08-31 | ||
| PCT/CN2022/116084 WO2023030363A1 (en) | 2021-08-31 | 2022-08-31 | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530315A JP2024530315A (ja) | 2024-08-16 |
| JP2024530315A5 true JP2024530315A5 (https=) | 2025-09-03 |
Family
ID=85410866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513277A Pending JP2024530315A (ja) | 2021-08-31 | 2022-08-31 | Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317743A1 (https=) |
| EP (1) | EP4396180A4 (https=) |
| JP (1) | JP2024530315A (https=) |
| KR (1) | KR20240054327A (https=) |
| CN (1) | CN118215660A (https=) |
| AU (1) | AU2022336557A1 (https=) |
| CA (1) | CA3230314A1 (https=) |
| IL (1) | IL311106A (https=) |
| MX (1) | MX2024002465A (https=) |
| TW (1) | TW202328125A (https=) |
| WO (1) | WO2023030363A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296582A (en) | 2020-04-15 | 2022-11-01 | Beigene Ltd | bcl-2 inhibitor |
| WO2026002056A1 (en) | 2024-06-26 | 2026-01-02 | Beone Pharmaceutical (Suzhou) Co., Ltd. | A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138588A2 (en) * | 2009-05-26 | 2010-12-02 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2668180B1 (en) * | 2011-01-25 | 2018-08-01 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors for use in the treatment of cancer |
| SG11202009933WA (en) * | 2018-04-29 | 2020-11-27 | Beigene Ltd | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2022
- 2022-08-31 EP EP22863498.6A patent/EP4396180A4/en active Pending
- 2022-08-31 JP JP2024513277A patent/JP2024530315A/ja active Pending
- 2022-08-31 CA CA3230314A patent/CA3230314A1/en active Pending
- 2022-08-31 AU AU2022336557A patent/AU2022336557A1/en active Pending
- 2022-08-31 WO PCT/CN2022/116084 patent/WO2023030363A1/en not_active Ceased
- 2022-08-31 MX MX2024002465A patent/MX2024002465A/es unknown
- 2022-08-31 CN CN202280058535.7A patent/CN118215660A/zh active Pending
- 2022-08-31 IL IL311106A patent/IL311106A/en unknown
- 2022-08-31 TW TW111132850A patent/TW202328125A/zh unknown
- 2022-08-31 KR KR1020247010341A patent/KR20240054327A/ko active Pending
-
2024
- 2024-02-27 US US18/589,022 patent/US20240317743A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536960A5 (https=) | ||
| JP2024530315A5 (https=) | ||
| ES2527768T5 (es) | Sales cristalinas de sitagliptina | |
| CN101068793B (zh) | Hiv整合酶抑制剂的钾盐 | |
| JP4142621B2 (ja) | 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法 | |
| TW202335670A (zh) | ｛［５—（３—氯苯基）—３—羥基吡啶—２—羰基］胺基｝乙酸之固體型式，其組合物及用途 | |
| RS55353B2 (sr) | Tenofovir alafenamid hemifumarat | |
| JP2022512824A5 (https=) | ||
| JP2025508071A5 (https=) | ||
| TWI377205B (en) | Isoxazoline derivative and novel process for its preparation | |
| TW201617315A (zh) | 異吲哚啉酮衍生物 | |
| IL297041A (en) | Inhibitors of human immunodeficiency virus replication | |
| JP2025102940A5 (https=) | ||
| JP2025529483A (ja) | Ａｐｘ３３３０の塩及びエステルならびにその治療的使用 | |
| TW201625549A (zh) | 經取代之吡啶基－環烷基－羧酸、包含其之組合物及其用途 | |
| TWI808069B (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
| WO2019119832A1 (zh) | 用于代谢性疾病治疗的化合物及其制备方法和应用 | |
| CN111592485A (zh) | 盐酸替罗非班及其游离碱的晶型及其制备方法 | |
| JP7448541B2 (ja) | 選択的エストロゲン受容体分解剤の新規な塩 | |
| CN118401525A (zh) | 吡唑并[3,4-d]嘧啶化合物的固体形式 | |
| JP2025508051A5 (https=) | ||
| JP2004530706A (ja) | 純粋な結晶形態にある５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニル及び合成方法 | |
| CA3244893A1 (en) | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4-YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC AND ITS CRYSTALLINE FORMS FOR USE AS A PHARMACEUTICALLY ACTIVE COMPOUND | |
| JP2024520897A5 (https=) | ||
| JP2002505254A (ja) | パロキセチン塩 |